Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX ABIVAX Société Anonyme	$6.05 +2.7%	$6.79	$5.50 ▼ $16.63	$383.47M	-0.2	124,239 shs	130,969 shs
PHAR Pharming Group	$8.32 -3.5%	$8.73	$6.65 ▼ $11.30	$566.02M	-0.1	6,222 shs	13,668 shs
SLRN Acelyrin	$2.74 +9.2%	$2.38	$1.85 ▼ $7.25	$252.78M	1.12	1.21 million shs	2.67 million shs
ZYME Zymeworks	$11.92 +2.6%	$13.45	$7.97 ▼ $17.70	$829.36M	1.13	595,022 shs	523,406 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX ABIVAX Société Anonyme	+2.72%	-14.67%	-17.46%	-17.01%	-56.91%
PHAR Pharming Group	+0.12%	-4.42%	-7.71%	-20.46%	-22.68%
SLRN Acelyrin	+9.16%	+7.87%	+1.86%	-16.97%	-58.10%
ZYME Zymeworks	+2.58%	-3.48%	-6.44%	-19.35%	+29.14%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX ABIVAX Société Anonyme	2.2312 of 5 stars	3.5	2.0	2.9	0.8	0.6
PHAR Pharming Group	2.3462 of 5 stars	3.5	3.0	3.2	0.0	0.6
SLRN Acelyrin	3.1032 of 5 stars	3.2	2.0	3.3	3.3	1.3
ZYME Zymeworks	2.6461 of 5 stars	3.4	0.0	3.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX ABIVAX Société Anonyme	3.00	Buy	$38.00	528.10% Upside
PHAR Pharming Group	3.00	Buy	$30.00	260.58% Upside
SLRN Acelyrin	2.40	Hold	$9.60	250.36% Upside
ZYME Zymeworks	2.88	Moderate Buy	$21.00	76.17% Upside

Current Analyst Ratings Breakdown

Latest ABVX, ZYME, PHAR, and SLRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/20/2025	ABVX ABIVAX Société Anonyme	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$12.00
3/20/2025	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00 ➝ $37.00
3/14/2025	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $39.00
3/14/2025	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00 ➝ $37.00
3/11/2025	ZYME Zymeworks	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/10/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $13.00
3/7/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $19.00
1/10/2025	ABVX ABIVAX Société Anonyme	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$33.00 ➝ $33.00
1/7/2025	SLRN Acelyrin	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $3.00
1/7/2025	SLRN Acelyrin	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $6.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	$3.37 per share	N/A
PHAR Pharming Group	$297.20M	1.90	$0.09 per share	91.82	$3.26 per share	2.55
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
ZYME Zymeworks	$76.30M	10.87	N/A	N/A	$6.63 per share	1.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX ABIVAX Société Anonyme	-$159.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	-$10.55M	-$0.17	N/A	277.33	N/A	-6.09%	-7.65%	-3.82%	5/6/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.50	N/A	N/A	N/A	N/A	-44.12%	-39.02%	5/13/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.61	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	5/1/2025 (Estimated)

Latest ABVX, ZYME, PHAR, and SLRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	ZYME Zymeworks	-$0.45	N/A	N/A	N/A	$20.65 million	N/A
3/19/2025	Q4 2024	SLRN Acelyrin	-$0.86	-$0.79	+$0.07	-$0.79	N/A	N/A
3/13/2025	Q4 2024	PHAR Pharming Group	$0.07	$0.05	-$0.02	$0.05	$76.67 million	$92.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX ABIVAX Société Anonyme	0.48	3.04	N/A
PHAR Pharming Group	0.41	3.53	2.76
SLRN Acelyrin	N/A	7.15	7.15
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX ABIVAX Société Anonyme	47.91%
PHAR Pharming Group	0.03%
SLRN Acelyrin	87.31%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ABVX ABIVAX Société Anonyme	N/A
PHAR Pharming Group	2.07%
SLRN Acelyrin	13.60%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX ABIVAX Société Anonyme	61	63.38 million	N/A	Not Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
SLRN Acelyrin	135	100.71 million	86.68 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

ABVX, ZYME, PHAR, and SLRN Headlines

Recent News About These Companies

Zymeworks Inc. (NYSE:ZYME) Director Purchases $51,664.75 in Stock

April 3 at 5:53 AM | insidertrades.com

Zymeworks Inc. sees insider purchases totaling $1.5 million

April 2 at 7:31 PM | investing.com

Ecor1 Capital, Llc Buys 43,848 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

March 28, 2025 | marketbeat.com

Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 43,848 Shares of Stock

March 28, 2025 | insidertrades.com

Zymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

March 26, 2025 | finanznachrichten.de

Insiders Make Huge Purchases of These 4 Biotech Stocks

March 26, 2025 | 247wallst.com

Zymeworks to Engage Investors at Upcoming Conferences

March 26, 2025 | tipranks.com

Zymeworks Announces Participation in Upcoming Investor Conferences

March 26, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Director Acquires $296,772.12 in Stock

March 25, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Director Purchases $396,601.74 in Stock

March 25, 2025 | marketbeat.com

Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March

March 25, 2025 | msn.com

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

March 25, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 22,689 Shares

March 25, 2025 | insidertrades.com

Hillsdale Investment Management Inc. Purchases Shares of 230,025 Zymeworks Inc. (NYSE:ZYME)

March 24, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $1.77 Million Stock Holdings in Zymeworks Inc. (NYSE:ZYME)

March 23, 2025 | marketbeat.com

Insiders Are Spending Big: 15 Stocks Leading in March

March 22, 2025 | insidermonkey.com

Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

March 21, 2025 | marketbeat.com

Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 56,277 Shares of Stock

March 20, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 58,306 Shares

March 20, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 56,277 Shares

March 20, 2025 | insidertrades.com

Platinum Investment Management Ltd. Has $4.49 Million Holdings in Zymeworks Inc. (NYSE:ZYME)

March 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

4 Healthcare Stocks With Massive Gains—and More to Come
By Sarah Horvath | March 29, 2025
View 4 Healthcare Stocks With Massive Gains—and More to Come
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
By Leo Miller | March 13, 2025
View 3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Which Healthcare Stock Is the Best Buy Right Now?
By Nathan Reiff | March 31, 2025
View Which Healthcare Stock Is the Best Buy Right Now?
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
By Leo Miller | March 6, 2025
View Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
Pharma Frenzy: Volatility Ignites Biotech Sector
By Jeffrey Neal Johnson | March 25, 2025
View Pharma Frenzy: Volatility Ignites Biotech Sector

ABVX, ZYME, PHAR, and SLRN Company Descriptions

ABIVAX Société Anonyme NASDAQ:ABVX

$6.05 +0.16 (+2.72%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$6.30 +0.25 (+4.12%)

As of 04/2/2025 04:22 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Pharming Group NASDAQ:PHAR

$8.32 -0.30 (-3.48%)

Closing price 04/2/2025 03:42 PM Eastern

Extended Trading

$7.90 -0.42 (-4.99%)

As of 06:52 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Acelyrin NASDAQ:SLRN

$2.74 +0.23 (+9.16%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$2.52 -0.23 (-8.21%)

As of 08:01 AM Eastern

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Zymeworks NYSE:ZYME

$11.92 +0.30 (+2.58%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$11.47 -0.45 (-3.81%)

As of 07:49 AM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time